RecruitingNCT07557849
Multicentric Database for KRAS Mutant Pancreatic Cancer
Construction and Maintenance of a Precision Subtyping-Based Clinical Cohort for Targeted Therapy in KRAS-Mutant Pancreatic Cancer
Sponsor
Fudan University
Enrollment
1,000 participants
Start Date
May 22, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
Construction and Maintenance of a Precision Subtyping-Based Clinical Cohort for Targeted Therapy in KRAS-Mutant Pancreatic Cancer
Eligibility
Inclusion Criteria4
- No restrictions on age, gender, or performance status score;
- Pathologically or cytologically confirmed pancreatic adenocarcinoma; ③ Known KRAS mutation subtype and has received treatment with KRAS-targeted agents;
- ④ Able to comply with the study visit schedule requirements;
- ⑤ Voluntarily participate and sign the informed consent form.
Exclusion Criteria2
- Non-neoplastic pancreatic lesions;
- Non-primary pancreatic neoplastic lesions; ③ Unable to comply with the study visit schedule requirements; ④ Refuse to participate and sign the informed consent form.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07557849
Related Trials
Pancreatic Cancer Screening Using the Enzeavour Assay in Japan
NCT076058191 location
Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors
NCT068436291 location
An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer
NCT075895692 locations
Validation of the Odesa Criteria 2026 for Autoimmune Pancreatitis
NCT075368412 locations
HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
NCT071315141 location